The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Moderate to strong cytoplasmic staining was observed in most malignancies. Several renal cancers were negative or weakly stained.
Most malignant cells displayed moderate to strong cytoplasmic immunoreactivity with a granular pattern. A few cases of malignant gliomas were weakly stained.
A majority of malignant cells displayed moderate to strong cytoplasmic staining with a granular pattern. Several cases of malignant gliomas, thyroid and renal cancers were weakly stained or negative.
A majority of malignant cells showed moderate cytoplasmic immunoreactivity. A few cases of malignant melanomas were strongly stained. A majority of malignant gliomas, renal, skin, lung and cervical cancers were negative or weakly stained.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
